XHKG
6821
Market cap4.35bUSD
Dec 05, Last price
78.05HKD
1D
0.52%
1Q
-18.44%
IPO
-70.47%
Name
Asymchem Laboratories Tianjin Co Ltd
Chart & Performance
P/E
24.88
P/S
4.07
EPS
2.85
Div Yield, %
2.53%
Shrs. gr., 5y
1.77%
Rev. gr., 5y
18.73%
Revenues
5.80b
-25.82%
Net income
949m
-58.17%
CFO
1.25b
-64.66%
Dividend
Jun 13, 20241.9767 HKD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization services in Mainland China and internationally. The company offers drug research and development, and manufacturing services for pharmaceutical and biotech companies. Its solutions range from early clinical stage to commercial stage, including research and development, and cGMP production of advanced intermediates, active pharmaceutical ingredients, and formulations, as well as clinical research services. The company also engages in the provision of pharmaceutical analysis and testing services; sale, wholesale, and retail of drugs; and pharmaceutical science and technology development activities. The company was founded in 1999 and is headquartered in Tianjin, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||